Guardant Health (NASDAQ:GH) Posts Quarterly Earnings Results, Misses Estimates By $0.15 EPS

Guardant Health (NASDAQ:GH - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.15), Zacks reports. The company had revenue of $201.81 million for the quarter, compared to analysts' expectations of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. Guardant Health updated its FY 2025 guidance to EPS.

Guardant Health Stock Down 9.6 %

Shares of GH traded down $4.53 on Friday, hitting $42.87. 5,735,530 shares of the stock traded hands, compared to its average volume of 2,122,650. Guardant Health has a 1 year low of $15.81 and a 1 year high of $50.89. The stock's 50 day moving average is $40.19 and its two-hundred day moving average is $31.59. The firm has a market capitalization of $5.30 billion, a P/E ratio of -12.04 and a beta of 1.32.

Wall Street Analysts Forecast Growth

Several analysts have commented on GH shares. Raymond James reaffirmed an "outperform" rating and set a $59.00 price objective (up from $39.00) on shares of Guardant Health in a research note on Friday. Stifel Nicolaus increased their target price on Guardant Health from $45.00 to $53.00 and gave the stock a "buy" rating in a research note on Friday. The Goldman Sachs Group increased their target price on Guardant Health from $49.00 to $56.00 and gave the stock a "buy" rating in a research note on Friday. Barclays started coverage on Guardant Health in a research note on Thursday, January 23rd. They set an "overweight" rating and a $60.00 target price for the company. Finally, JPMorgan Chase & Co. increased their target price on Guardant Health from $50.00 to $55.00 and gave the stock an "overweight" rating in a research note on Friday. Eighteen research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $44.78.

Insider Buying and Selling

In other news, Director Musa Tariq sold 2,320 shares of the stock in a transaction on Friday, December 13th. The shares were sold at an average price of $35.00, for a total value of $81,200.00. Following the completion of the sale, the director now owns 2,676 shares of the company's stock, valued at $93,660. This represents a 46.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last quarter, insiders sold 2,768 shares of company stock valued at $98,798. Insiders own 5.50% of the company's stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.